Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jun 15;189(12):1564-7.
doi: 10.1164/rccm.201312-2121LE.

Plasma complement levels are associated with primary graft dysfunction and mortality after lung transplantation

Rupal J Shah  1 , Amir M Emtiazjoo, Joshua M Diamond, Patricia A Smith, David W Roe, Keith M Wille, Jonathan B Orens, Lorraine B Ware, Ann Weinacker, Vibha N Lama, Sangeeta M Bhorade, Scott M Palmer, Maria Crespo, David J Lederer, Edward Cantu, George J Eckert, Jason D Christie, David S Wilkes
Affiliations
Clinical Trial

Plasma complement levels are associated with primary graft dysfunction and mortality after lung transplantation

Rupal J Shah et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Plasma C5a concentration at each time point in subjects without primary graft dysfunction (PGD) (dashed line) and with grade 3 PGD (solid line). The P value indicates that the difference in C5a concentration (represented by the slope of the line) between the 6-hour time point and the 24-hour time point is significantly greater in those with PGD compared with those without. (B) Plasma C4a concentration at each time point in subjects without PGD (dashed line) and with grade 3 PGD (solid line). The P value indicates that the difference in C4a concentration between the preoperative time point and the 6-hour time point (represented by the slope of the line) is significantly greater in those with PGD compared with those without.
See this image and copyright information in PMC

References

    1. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group On Primary Lung Graft Dysfunction Part II: definition. A consensus statement of The International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005;24:1454–1459. - PubMed
    1. Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, Lederer DJ, Cantu E, Kohl BA, Lama VN, et al. Lung Transplant Outcomes Group. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2013;187:527–534. - PMC - PubMed
    1. Strainic MG, Shevach EM, An F, Lin F, Medof ME. Absence of signaling into CD4⁺ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3⁺ regulatory T cells. Nat Immunol. 2013;14:162–171. - PMC - PubMed
    1. Frank MM. Complement in the pathophysiology of human disease. N Engl J Med. 1987;316:1525–1530. - PubMed
    1. Asgari E, Zhou W, Sacks S. Complement in organ transplantation. Curr Opin Organ Transplant. 2010;15:486–491. - PMC - PubMed